文献速递脑血管病

卒中患者中非甾体抗炎药过敏标签与死亡及心血管结局相关

NSAID Allergy Labels Associated With Mortality and Cardiovascular Outcomes in Stroke.
PubMed 文献 · Stroke · 2024-11-19

该研究基于香港2008至2014年电子健康记录,比较卒中患者与一般人群的药物过敏标签流行率,并分析非甾体抗炎药(NSAID)过敏标签与卒中后结局的关系。结果显示卒中患者NSAID过敏标签流行率为1.8%,且与更高的死亡率、外周血管病和主要不良心血管事件相关;激发试验证实多数标签为误标。

要点

  • 卒中患者NSAID过敏标签流行率为1.8%,该类患者急性卒中后及随访中接受阿司匹林处方的可能性显著更低。
  • 携带NSAID过敏标签的卒中患者死亡、外周血管病及主要不良心血管事件风险显著更高。
  • 接受激发试验的5例中4例(80%)为阴性并去标签,提示误标率高。

核心结论

  • NSAID过敏标签在卒中患者中显著更常见,并与过度死亡、外周血管病和主要不良心血管事件相关。
  • 鉴于误标过敏比例高,多学科神经-过敏干预可能具有改善患者结局的潜力。

研究设计与样本

  • 研究为纵向与横断面相结合的设计,比较2008至2014年香港电子健康记录中一般人群与缺血性卒中患者的过敏标签流行率。
  • 比较携带与不携带最常见标签(即NSAID)的卒中患者之间的结局,并通过激发试验确认NSAID过敏误标率。

主要发现

  • 与一般人群(n=702 966)相比,卒中患者(n=235)对心血管和造血系统药物的标签流行率为19.5% vs 9.2%(OR 2.4,95%CI 1.74-3.32,P<0.001)。
  • 卒中患者对放射学及诊断试剂的标签流行率为4.2% vs 0.9%(OR 4.82,95%CI 2.56-9.08,P<0.001)。
  • 最常见的标签为NSAID,流行率1.8%。
  • 携带NSAID过敏标签的卒中患者在急性卒中后接受阿司匹林处方的可能性显著更低(OR 0.24,95%CI 0.09-0.60,P=0.003),随访中亦更低(OR 0.22,95%CI 0.08-0.56,P=0.002)。
  • 中位随访时间为6.7年(6499±2.49患者年);携带NSAID过敏标签的卒中患者死亡(OR 7.44,95%CI 2.44-23.18,P<0.001)、外周血管病(OR 9.35,95%CI 1.95-44.86,P=0.005)和主要不良心血管事件(OR 6.09,95%CI 2.00-18.58,P=0.001)均显著更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mislabeled drug allergy can restrict future prescriptions and medication use, but its prevalence and impact among patients with stroke remain unknown. This study investigated the prevalence of the most commonly labeled drug allergies, their accuracy, and their impact among patients with stroke. METHODS: In this combined longitudinal and cross-sectional study, we compared the prevalence of allergy labels among the general population and patients with ischemic stroke between 2008 and 2014 from electronic health care records in Hong Kong. Outcomes between patients with stroke with or without the most prevalent labels (ie, NSAID) were compared. Rate of mislabeled NSAID allergy was confirmed by provocation testing. RESULTS: Compared with the general population (n=702 966), patients with stroke had more labels (n=235) to cardiovascular and hematopoietic system (prevalence, 19.5% versus 9.2%; odds ratio [OR], 2.4 [95% CI, 1.74-3.32]; P<0.001) and radiographic and diagnostic agents (prevalence, 4.2% versus 0.9%; OR, 4.82 [95% CI, 2.56-9.08]; P<0.001). The most common labels were to NSAID (prevalence, 1.8%). Patients with NSAID allergy labels were significantly less likely to be prescribed aspirin after acute stroke (OR, 0.24 [95% CI, 0.09-0.60]; P=0.003) and on follow-up (OR, 0.22 [95% CI, 0.08-0.56]; P=0.002). The median duration of follow-up was 6.7 years (6499±2.49 patient-years). Patients with stroke with NSAID allergy labels also experienced significantly higher mortality (OR, 7.44 [95% CI, 2.44-23.18]; P<0.001), peripheral vascular disease (OR, 9.35 [95% CI, 1.95-44.86]; P=0.005), and major adverse cardiovascular events (OR, 6.09 [95% CI, 2.00-18.58]; P=0.001) in the poststroke period. Patients with NSAID allergy labels (who remained alive and could consent) were referred for allergist assessment and offered drug provocation testing. The majority (80%; 4/5) had negative provocation tests and were delabeled. CONCLUSIONS: NSAID allergy labels were significantly more prevalent among patients with stroke, associated with excessive mortality, peripheral vascular disease, and major adverse cardiovascular events. Given the high rate of mislabeled allergies, multidisciplinary neuro-allergy interventions could have the potential to improve patient outcomes.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Tsui CCW, Mak HWF, Leung WCY, et al. NSAID Allergy Labels Associated With Mortality and Cardiovascular Outcomes in Stroke. Stroke. 2024. PMID: 39559853. doi:10.1161/STROKEAHA.124.047921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。